<DOC>
	<DOCNO>NCT02114684</DOCNO>
	<brief_summary>This open label randomize control clinical trial compare two regimen treatment smear-positive pulmonary TB , among patient previously treat TB . The primary objective determine moxifloxacin-containing regimen , substitute moxifloxacin ethambutol , 24 week duration superior control regimen 24 week duration improve treatment outcome patient recurrent TB shorten duration TB treatment .</brief_summary>
	<brief_title>Improving Retreatment Success ( IMPRESS )</brief_title>
	<detailed_description>Intervention Arm :12 month ( 6 month treatment + 6 month post treatment follow ) Control Arm :12 month ( 8 month treatment + 6 month post treatment follow ) Total sample size 330 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Adults â‰¥ 18 year age Previous history antiTB chemotherapy HIV status : HIV infect uninfected patient allow study : All patient must agree HIV test confirm HIV status . Patients already ARVs allow study provide ART regimen contraindicate study agent . HIV infect patient CD4 count irrespective ART commencement duration include study Smear positive Gene Xpert positive pulmonary tuberculosis Rifampicin susceptible determine Gene Xpert screen . Gene Xpert use determine rifampicin resistance , hence study team make aware resistance within 48 hour prior study enrolment . Karnofsky score great 70 Female candidate reproductive potential must agree use two reliable method contraception study : barrier method contraception ( condoms cervical cap ) together another reliable form contraceptive ( condom spermicidal agent , diaphragm cervical cap spermicide , Intrauterine Device ( IUD ) , hormonebased contraceptive ) A negative pregnancy test Laboratory parameter do , 14 day prior , screen : Haemoglobin level least 7.0 g/dL Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) activity le 3 time upper limit normal Serum total bilirubin level le 2.5 time upper limit normal Creatinine clearance ( CrCl ) level great 60 mls/min Platelet count least 50 x109cells/L Serum potassium great 3.0 mmol/L Patients Nevirapine ( NVP ) contain ART regimen screen Pregnant breastfeeding Received antibiotic active M. tuberculosis last 14 day ( e.g . fluoroquinolones , macrolides , standard antituberculosis drug ) . Patients know M. tuberculosis resistance study drug screen History prolong QT syndrome current plan therapy quinidine , procainamide , amiodarone , sotalol , ziprasidone intensive phase tuberculosis treatment . Known allergy intolerance study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>